Advertisement

Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials)

Published:November 19, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.10.029
      Women have higher bleeding complication and mortality rates after percutaneous coronary interventions (PCI). The contribution of female gender to bleeding and mortality is poorly understood. We evaluated the effect of gender and bleeding on outcomes of patients treated with bivalirudin during PCI by performing a patient-level pooled analysis of 3 randomized controlled trials (the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, Acute Catheterization and Urgent Intervention Triage strategY, and Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) treatment in patients undergoing PCI. Of 14,784 patients, 7,413 patients received bivalirudin (1,870 women) and 7,371 patients received heparin + GPI (1,910 women). Women had significantly higher 30-day non–coronary artery bypass grafting (CABG)-related major bleeding rates (7.6% vs 3.8%, p <0.0001). After multivariate adjustment, female gender increased the hazard of major bleeding by 80% (hazard ratio 1.80, 95% confidence interval 1.52 to 2.11, p <0.001). Furthermore, women had a higher 1-year mortality rate (3.7% vs 2.7%, p = 0.002) than men; 30-day major bleeding was the strongest independent predictor of 1-year mortality in women (hazard ratio 2.48, 95% confidence interval 1.57 to 3.91, p = 0.001). Bivalirudin therapy in women reduced 30-day non–CABG-related major bleeding (5.6% vs 9.7%, p <0.0001) and 1-year mortality (2.9% vs 4.4%, p = 0.02) compared to standard therapy. In conclusion, in this cohort of patients treated for acute coronary syndrome and ST-segment elevation myocardial infarction, women have a near 2-fold increase in bleeding complications compared to men after PCI. Bleeding complications rather than gender is the strongest independent predictor of 1-year mortality in patients undergoing PCI. Furthermore, we observed a more pronounced clinical benefit in women treated with bivalirudin including a 44% reduction in major bleeding and a significant reduction in mortality rates at 1 year.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cheng C.
        • Yeh K.H.
        • Chang H.W.
        • Yu T.H.
        • Chen Y.H.
        • Chai H.T.
        • Yip H.K.
        Comparison of baseline characteristics, clinical features, angiographic results, and early outcomes in men vs women with acute myocardial infarction undergoing primary coronary intervention.
        Chest. 2004; 126: 47-53
        • King K.M.
        • Ghali W.A.
        • Faris P.D.
        • Curtis M.J.
        • Galbraith P.D.
        • Graham M.M.
        • Knudtson M.L.
        Sex differences in outcomes after cardiac catheterization: effect modification by treatment strategy and time.
        JAMA. 2004; 291: 1220-1225
        • Vakili B.A.
        • Kaplan R.C.
        • Brown D.L.
        Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction.
        Circulation. 2001; 104: 3034-3038
        • Radovanovic D.
        • Erne P.
        • Urban P.
        • Bertel O.
        • Rickli H.
        • Gaspoz J.M.
        Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS Plus Registry.
        Heart. 2007; 93: 1369-1375
        • Moscucci M.
        • Fox K.A.
        • Cannon C.P.
        • Klein W.
        • Lopez-Sendon J.
        • Montalescot G.
        • White K.
        • Goldberg R.J.
        Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).
        Eur Heart J. 2003; 24: 1815-1823
        • Argulian E.
        • Patel A.
        • Abramson J.L.
        • Kulkarni A.
        • Champney K.
        • Palmer S.
        • Weintraub W.
        • Wenger N.K.
        • Vaccarino V.
        Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions.
        Am J Cardiol. 2006; 98: 48-53
        • Feit F.
        • Voeltz M.D.
        • Attubato M.J.
        • Lincoff A.M.
        • Chew D.P.
        • Bittl J.A.
        • Topol E.J.
        • Manoukian S.V.
        Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.
        Am J Cardiol. 2007; 100: 1364-1369
        • Kinnaird T.D.
        • Stabile E.
        • Mintz G.S.
        • Lee C.W.
        • Canos D.A.
        • Gevorkian N.
        • Pinnow E.E.
        • Kent K.M.
        • Pichard A.D.
        • Satler L.F.
        • Weissman N.J.
        • Lindsay J.
        • Fuchs S.
        Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions.
        Am J Cardiol. 2003; 92: 930-935
        • Huynh T.
        • Theroux P.
        • Snapinn S.
        • Wan Y.
        Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
        Am Heart J. 2003; 146: 668-673
        • EPILOG Investigators
        Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
        N Engl J Med. 1997; 336: 1689-1696
      1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation.
        N Engl J Med. 1994; 330: 956-961
        • Fernandes L.S.
        • Tcheng J.E.
        • O'Shea J.C.
        • Weiner B.
        • Lorenz T.J.
        • Pacchiana C.
        • Berdan L.G.
        • Maresh K.J.
        • Joseph D.
        • Madan M.
        • Mann T.
        • Kilaru R.
        • Hochman J.S.
        • Kleiman N.S.
        Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study.
        J Am Coll Cardiol. 2002; 40: 1085-1091
        • Cho L.
        • Topol E.J.
        • Balog C.
        • Foody J.M.
        • Booth J.E.
        • Cabot C.
        • Kleiman N.S.
        • Tcheng J.E.
        • Califf R.
        • Lincoff A.M.
        Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation in percutaneous transluminal coronary angioplasty to improve long-term outcome with abciximab GP IIb/IIIa blockade. Evaluation of platelet IIb/IIIa Inhibitor for Stent.
        J Am Coll Cardiol. 2000; 36: 381-386
        • Razakjr O.A.
        • Tan H.C.
        • Yip W.L.
        • Lim Y.T.
        Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.
        J Interv Cardiol. 2005; 18: 33-37
        • Eikelboom J.W.
        • Mehta S.R.
        • Anand S.S.
        • Xie C.
        • Fox K.A.
        • Yusuf S.
        Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.
        Circulation. 2006; 114: 774-782
        • Manoukian S.V.
        • Feit F.
        • Mehran R.
        • Voeltz M.D.
        • Ebrahimi R.
        • Hamon M.
        • Dangas G.D.
        • Lincoff A.M.
        • White H.D.
        • Moses J.W.
        • King 3rd, S.B.
        • Ohman E.M.
        • Stone G.W.
        Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.
        J Am Coll Cardiol. 2007; 49: 1362-1368
        • Lincoff A.M.
        • Bittl J.A.
        • Harrington R.A.
        • Feit F.
        • Kleiman N.S.
        • Jackman J.D.
        • Sarembock I.J.
        • Cohen D.J.
        • Spriggs D.
        • Ebrahimi R.
        • Keren G.
        • Carr J.
        • Cohen E.A.
        • Betriu A.
        • Desmet W.
        • Kereiakes D.J.
        • Rutsch W.
        • Wilcox R.G.
        • de Feyter P.J.
        • Vahanian A.
        • Topol E.J.
        Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
        JAMA. 2003; 289: 853-863
        • Stone G.W.
        • White H.D.
        • Ohman E.M.
        • Bertrand M.E.
        • Lincoff A.M.
        • McLaurin B.T.
        • Cox D.A.
        • Pocock S.J.
        • Ware J.H.
        • Feit F.
        • Colombo A.
        • Manoukian S.V.
        • Lansky A.J.
        • Mehran R.
        • Moses J.W.
        Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis form the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
        Lancet. 2007; 369: 907-919
        • Stone G.W.
        • Witzenbichler B.
        • Guagliumi G.
        • Peruga J.Z.
        • Brodie B.R.
        • Dudek D.
        • Kornowski R.
        • Hartmann F.
        • Gersh B.J.
        • Pocock S.J.
        • Dangas G.
        • Wong S.C.
        • Kirtane A.J.
        • Parise H.
        • Mehran R.
        Bivalirudin during primary PCI in acute myocardial infarction.
        N Engl J Med. 2008; 358: 2218-2230
        • Shahzad A.
        • Kemp I.
        • Mars C.
        • Wilson K.
        • Roome C.
        • Cooper R.
        • Andron M.
        • Appleby C.
        • Fisher M.
        • Khand A.
        • Kunadian B.
        • Mills J.D.
        • Morris J.L.
        • Morrison W.L.
        • Munir S.
        • Palmer N.D.
        • Perry R.A.
        • Ramsdale D.R.
        • Velavan P.
        • Stables R.H.
        • HEAT-PPCI Trial Investigators
        Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.
        Lancet. 2014; 384: 1849-1858
        • Cavender M.A.
        • Sabatine M.S.
        Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
        Lancet. 2014; 384: 599-606
        • Stone G.W.
        • Bertrand M.
        • Colombo A.
        • Dangas G.
        • Farkouh M.E.
        • Feit F.
        • Lansky A.J.
        • Lincoff A.M.
        • Mehran R.
        • Moses J.W.
        • Ohman M.
        • White H.D.
        Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
        Am Heart J. 2004; 148: 764-775
        • Mehran R.
        • Brodie B.
        • Cox D.A.
        • Grines C.L.
        • Rutherford B.
        • Bhatt D.L.
        • Dangas G.
        • Feit F.
        • Ohman E.M.
        • Parise H.
        • Fahy M.
        • Lansky A.J.
        • Stone G.W.
        The Harmonizing outcomes with RevasculariZatiON and stents in acute myocardial infarction (HORIZONS-AMI) trial: study design and rationale.
        Am Heart J. 2008; 156: 44-56
        • Hochman J.S.
        • McCabe C.H.
        • Stone P.H.
        • Becker R.C.
        • Cannon C.P.
        • DeFeo-Fraulini T.
        • Thompson B.
        • Steingart R.
        • Knatterud G.
        • Braunwald E.
        Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB.
        J Am Coll Cardiol. 1997; 30: 141-148
        • Peterson E.D.
        • Lansky A.J.
        • Kramer J.
        • Anstrom K.
        • Lanzilotta M.J.
        Effect of gender on the outcomes of contemporary percutaneous coronary intervention.
        Am J Cardiol. 2001; 88: 359-364
        • Chacko M.
        • Lincoff A.M.
        • Wolski K.E.
        • Cohen D.J.
        • Bittl J.A.
        • Lansky A.J.
        • Tsuchiya Y.
        • Betriu A.
        • Yen M.H.
        • Chew D.P.
        • Cho L.
        • Topol E.J.
        Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
        Am Heart J. 2006; 151: 1032.e1-1032.e7
        • Sadeghi H.M.
        • Stone G.W.
        • Grines C.L.
        • Mehran R.
        • Dixon S.R.
        • Lansky A.J.
        • Fahy M.
        • Cox D.A.
        • Garcia E.
        • Tcheng J.E.
        • Griffin J.J.
        • Stuckey T.D.
        • Turco M.
        • Carroll J.D.
        Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.
        Circulation. 2003; 108: 2769-2775
        • Mehran R.
        • Pocock S.
        • Nikolsky E.
        • Dangas G.D.
        • Clayton T.
        • Claessen B.E.
        • Caixeta A.
        • Feit F.
        • Manoukian S.V.
        • White H.
        • Bertrand M.
        • Ohman E.M.
        • Parise H.
        • Lansky A.J.
        • Lincoff A.M.
        • Stone G.W.
        Impact of bleeding on mortality after percutaneous coronary intervention: results from a patient-level pooled analysis of the REPLACE-2 (Randomized evaluation of PCI Linking angiomax to reduced clinical events), ACUITY (Acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (Harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
        JACC Cardiovasc Interv. 2011; 4: 654-664
        • Gibson C.M.
        • Ten Y.
        • Murphy S.A.
        • Ciaglo L.N.
        • Southard M.C.
        • Lincoff A.M.
        • Waksman R.
        Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis).
        Am J Cardiol. 2007; 99: 1687-1690
        • Dangas G.D.
        • Mehran R.
        • Nikolsky E.
        • Claessen B.E.
        • Lansky A.J.
        • Brodie B.R.
        • Witzenbichler B.
        • Guagliumi G.
        • Peruga J.Z.
        • Dudek D.
        • Mockel M.
        • Caixeta A.
        • Parise H.
        • White H.
        • Stone G.W.
        Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis.
        J Am Coll Cardiol. 2011; 57: 2309-2316